2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
04/03/19Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option
WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has closed its previously announced underwritten public offering of 7,263,158 shares of its common stock at a price to the public of $4.75 per share for gross proceeds of approximately $34.5 million. The shares include 947,368 shares of common stock sold pursuant to ... 
Printer Friendly Version
03/29/19Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock
WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of an underwritten public offering of 6,315,790 shares of its common stock at a price to the public of $4.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Chiasma. In addition, Chiasma has granted the un... 
Printer Friendly Version
03/28/19Chiasma Announces Proposed Offering of Common Stock
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has commenced an underwritten public offering of its common stock. In addition, Chiasma expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is... 
Printer Friendly Version
03/21/19Chiasma Announces Three Poster Presentations at ENDO 2019
Presentations highlight persistent unmet needs in the maintenance treatment of adults with acromegaly WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced three poster presentations at ENDO 2019: The Endocrine Society’s Annual Meeting and Expo, which is being held March 23-26 in New Orleans. William Ludlam, MD, PhD, Senior... 
Printer Friendly Version
03/08/19Chiasma Reports Fourth Quarter and Year End 2018 Results
On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data, NDA submission expected by year-end 2019 WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today reported financial results for the fourth quarter and year ended... 
Printer Friendly Version
03/04/19Chiasma to Participate in Three Investor Conferences in March
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced that Mark Fitzpatrick, Chief Executive Officer and William Ludlam, MD, PhD, Senior Vice President of Clinical Development and Medical Affairs, will be presenting at the Cowen 39th Annual Health Care Conference and the Barclays Global Healthcare Conference. In addition, Mark F... 
Printer Friendly Version
02/28/19Chiasma Announces Support for Rare Disease Day 2019
WALTHAM, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced its support for the patient and research communities in recognition of Rare Disease Day 2019. “The theme of Rare Disease Day 2019, ‘Bridging health and social care,’ strikes at the heart of what we are working towards here at Chiasma to improve the lives of people afflicted... 
Printer Friendly Version
01/03/19Chiasma Previews Important Upcoming Milestones
CHIASMA OPTIMAL Phase 3 topline data expected in Q3 2019 Company anticipates submitting U.S. NDA by year-end 2019, assuming positive CHIASMA OPTIMAL data, and if accepted for filing, further expects a six-month FDA PDUFA review classification Key U.S. commercial readiness activities planned in 2019 WALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chro... 
Printer Friendly Version

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.